General Introduction

Jaap Koster
A regulatory body is like a professional body but it is not a membership organisation and its primary activity is to protect the public. Unlike professional bodies, it is established on the basis of legal mandate.

Regulatory bodies exercise a regulatory function, that is: imposing requirements, restrictions and conditions, setting standards in relation to any activity, and securing compliance, or enforcement.

Examples:
ANVISA: Brazilian
IGZ: Dutch
NRA’s (National Regulatory Agencies)
US-FDA: United States of America
EU: Guidelines and Directives to be implemented by individual memberstates.

“Non” regulatory bodies:
PIC/s; PDA; ICH; WHO ...
WHY BY LAW?

Effect of Medicines:
- Administered to (already) sick persons
- User has no capability to determine quality, effectiveness or safety
- Neither does the prescriber
- Molecules not part of regular metabolic system.
- Globally distributed (scale)

Risks have increased:
- < 1800:
  - Natural medicines
  - “Home made” Herbs etc
- 1800 - 1900:
  - Physics / Small Scale
- > 1900:
  - Medicinal Production
    - Local > National
    - European > Globally
- Existing Situation:
  - Complex Distribution System
EU LEGISLATION

Assurance of Quality (Medicinal Products)
Registration
GMP
Release by Company (QP vs RP)

Traceability of Medicinal Products
Across the Entire Supply Chain

Preventing introduction into the Supply Chain of non-approved Medicinal Products:
Counterfeit
Over due’s and/or Recall
Fit for their intended use,

Comply with the requirements of the dossier

Do not place patients at risk due to inadequate:
  safety,  
  quality  
  efficacy.

during the entire period being in the Supply Chain

Protected against Falsification/Counterfeit
DEVELOPMENT OF MEDICINES

Finding
Proof of Principle
Animal Studies
Clin. Phase I
Clin. Phase II
Clin. Phase III
Market

GLP
GMP GCP
GMP GDP

GMP
GCP
GLP
EU “LAW”

- **DIRECTIVES** for Medicinal Products
    - Combined in: 2001/83/EC
  - GMP: 2003/94/EC
  - GDP: 2013/C 68/01
PRINCIPLE OF LICENCED SUPPLY CHAIN SYSTEM

Manufactured Outside EU

Importer (EU)

Manufactured inside EU

Wholesaler

Wholesaler

Wholesaler

Farmacist

Drug-store

Recipient
• Wholesale distribution
  – Control of the Distribution Chain (maintaining Quality)
  – Prevent entering Falsified Medicines into the chain.
• Current Insights (compared with 1994 version)
  – Quality Systems
  – Risk Management
  – Warehouse-facilities
  – Qualification and Validation
  – Outsourcing
  – Falsified Medicines
## GDP VERSUS GMP CHAPTERS (EUDRALEX VOL 4)

<table>
<thead>
<tr>
<th>GDP Chapters (Other Documents)</th>
<th>GMP Chapters (Part I)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Quality Management</td>
<td>1. Pharmaceutical Quality System</td>
</tr>
<tr>
<td>2. Personnel</td>
<td>2. Personnel</td>
</tr>
<tr>
<td>3. Premises and Equipment</td>
<td>3. Premise and Equipment</td>
</tr>
<tr>
<td>4. Documentation</td>
<td>4. Documentation</td>
</tr>
<tr>
<td>5. Operations</td>
<td>5. Production</td>
</tr>
<tr>
<td>6. Complaints, Returns, Suspected Falsified Medicinal Products and Medicinal Product Recalls</td>
<td>6. Quality Control</td>
</tr>
<tr>
<td>7. Outsourced Activities</td>
<td>13. Outsourced Activities</td>
</tr>
<tr>
<td>9. Transportation</td>
<td>15. Self Inspection</td>
</tr>
<tr>
<td>10. Specific Provisions for Brokers</td>
<td></td>
</tr>
</tbody>
</table>
Annexes: (1-19) amongst others:
1-Manufacture of Sterile Medicinal Products
2-Manufacture of Biological active substances and Medicinal Products for Human Use
3-Manufacture of Radiopharmaceuticals
4-Manufacture of Veterinary Medicinal Products other than Immunological Veterinary Medicinal Products
6-Manufacture of Medicinal Gases
9-Manufacture of Liquids, Creams and Ointments
11-Computerised Systems
15-Qualification and Validation
17-Parametric Release
19-Reference and Retention Samples
Part II: Basic Requirements for Active Substances used as Starting Materials

Text of old Annex 18
EU GMP-GUIDELINE CONTENT

• Part III - GMP related documents
• Amongst others;

Site Master File
Q9 Quality Risk Management
Q10 Guidance on Pharmaceutical Quality System
MRA Batch Certificate
US-FDA OFFICES

Strategic locations around the world, including China, Europe, India and Latin America. Work closely with foreign governments, industry, and other stakeholders.
US-FDA 21CFR’S

US FDA Title 21 CFR Parts

• Part 11 - regulations on electronic records and electronic signatures
• Part 210 – CURRENT GOOD MANUFACTURING PRACTICE IN MANUFACTURING, PROCESSING, PACKING, OR HOLDING OF DRUGS; GENERAL
• Part 211 - CURRENT GOOD MANUFACTURING PRACTICE FOR FINISHED PHARMACEUTICALS
• Part 600 - Biological Products:General
  Part 601 - Licensing Biologics
  Part 610 - General Biological Products Standards
This guidance is intended to help manufacturers implementing modern quality systems and risk management approaches to meet the requirements of the FDA`s current good manufacturing practice (CGMP) regulations (21 CFR parts 210 and 211).

October 2014 Guidance (US) for Industry: Circumstances that Constitute Delaying, Denying, Limiting, or Refusing a Drug Inspection

On July 9, 2012, the Food and Drug Administration Safety and Innovation Act (FDASIA) (Public Law 112-144) was signed into law. Section 707 of FDASIA adds 501(j) to the Food, Drug, and Cosmetic Act (FD&C Act) to deem adulterated a drug that “has been manufactured, processed, packed, or held in any factory, warehouse, or establishment and the owner, operator, or agent of such factory, warehouse, or establishment delays, denies, or limits an inspection, or refuses to permit entry or inspection.” Section 707(b) of FDASIA requires the Food and Drug Administration (FDA) to issue guidance that defines the circumstances that would constitute delaying, denying, or limiting inspection, or refusing to permit entry or inspection, for purposes of section 501(j).
MODERNIZATION OF FDA

BACKGROUND AND PURPOSE
- August 2002, the FDA announced the Pharmaceutical CGMPs for the 21st Century Initiative
- Intent to integrate quality systems and risk management approaches

GOAL OF THE GUIDANCE
- Describes a comprehensive quality systems model
- Demonstrates how/where the elements of this comprehensive model can fit within the requirements of the CGMP regulations
- Bridge between the 1978 regulations and current understanding of quality systems

SCOPE OF THE GUIDANCE
- **NOT** intended to create new requirements for pharmaceutical manufacturing
- **NOT** intended to be a guide for the conduct of FDA inspections
- Explains how implementing comprehensive quality systems can help manufacturers achieve compliance with 21 CFR parts 210 and 211

ORGANIZATION OF THE GUIDANCE
An **FDA 483** is a form used by an FDA investigator following an inspection of your plant. It lists deficiencies in your quality system and potential non-compliance issues with GMP's. **These observations are based on the investigators interpretation of the GMP regulations as they apply to your specific situation.** During the investigator's closing meeting with management, you may be given a Form 483. The Form 483 is officially known as the "Notice of Inspection Observations."
WHAT IS 483

The content of a 483 may be handwritten, typed, completed in a PDF file and printed, or completed via the FDA's computer system called Turbo EIR

- Header information
- Observations
  - Annotation
- Signatures
- Converse side
- Addenda/amendments
USP Chapters

General chapters numbered above <1000> in USP–NF typically are informational and contain no mandatory requirements, unless specifically referenced in a monograph.

General chapters designated as below <1000> contain tests and procedures that are intended to apply to items recognized in USP or NF when called out in a monograph.

Example: General Chapter <1116> Microbiological Control and Monitoring of Aseptic Processing Environments
- <1229> Sterilization of Compendial Articles
- <1229.1> Steam Sterilization by Direct Contact
- <1229.2> Moist Heat Sterilization of Aqueous Liquids
- <1229.3> Monitoring of Bioburden
- <1229.4> Sterilizing Filtration of Liquids
- <1229.5> Biological Indicators for Sterilization
- <1229.6> Liquid Phase Sterilization
- <1229.7> Gaseous Sterilization
- <1229.8> Dry Heat Sterilization
- <1229.9> Physicochemical Integrators and Indicators for Sterilization
- <1229.10> Radiation Sterilization
- <1229.11> Vapor Phase Sterilization
WHO GUIDELINES FOR VACCINES

The World Health Organization brings together international experts in specific fields through its biological standardization programme to develop and revise specific recommendations for the production and quality control of vaccines of major international public health importance

http://www.who.int/biologicals/vaccines/en/

TRS 822, Annex 1 Biological products, GMP;

General topics and regulatory guidance

- Biotechnology and related topics
- Cell substrates
- WHO reference cell banks (RCBs)
- Clinical evaluation of vaccines
- Good Manufacturing Practices (GMP)
- Lot Release of Vaccines
- Non-clinical evaluation of vaccines
- Regulation of post approval changes to vaccines
- Regulation and quality control of vaccines
- Stability of vaccines and reference preparations
- Sterility testing
- Thiomersal
- Transmissible Spongiform Encephalities (TSE)
WHO GENERAL GMP GUIDELINES

TRS 986, Annex 2 WHO good manufacturing practices for pharmaceutical products: main principles

WHO GENERAL GMP GUIDELINES

TRS 961 - Forty-fifth Report (Geneva, 18–22 October 2010)
WHO Expert Committee on Specifications for Pharmaceutical Preparations

(2011; 440 pages)

Abstract

Annex 1: Release procedure of International Chemical Reference Substances;

Annex 2: WHO good practices for pharmaceutical microbiology laboratories;

Annex 3: WHO good manufacturing practices: main principles for pharmaceutical Products;

Annex 4: WHO good manufacturing practices for blood establishments (jointly with the Expert Committee on Biological Standardization);

Annex 5: WHO guidelines on good manufacturing practices for heating, ventilation and air-conditioning systems for non-sterile pharmaceutical dosage forms;

http://apps.who.int/medicinedocs/en/d/Js18652en/
(ICH) INTERNATIONAL CONFERENCE ON HARMONIZATION
ICH

- **ICH** — *International Conference on Harmonization* of technical requirements for registration of pharmaceuticals for human use
- Pioneered by EU in 1980s to facilitate the move towards single market for Pharmaceuticals
- Bilateral discussions between Europe, Japan and USA on possibility of harmonisation
- WHO Conference 1989 in Paris, agreement was reached to initiate a joint regulatory-industry initiative for international harmonisation
- ICH was borne in April 1990 (Brussels)
ICH Work Products (Quality Section)

- Stability – Q1 A – Q1 F
- Analytical Validation – Q2 A – Q2B
- Impurities – Q3 A – Q3 C
- Pharmacopoeias – Q4 – Q4 B
- Quality of Biotechnological Products – Q5 A – Q5 E
- Specifications – Q6 A – Q6
- Good Manufacturing Practice (APIs) – Q7 A
- Pharmaceutical Development – Q8
- Risk Assessment – Q9
- Pharmaceutical Quality Systems – Q10
- Development and Manufacturing – drug substances – Q11 (draft)
BRUSSELS 2003 (ICH)

The Regulatory Quality System

Quality Risk Management (Q9)

For companies with:
1. Good design and control strategies
2. Good Risk Management strategies
3. Good Quality Systems

Reduced intensity of Regulatory Oversight:
1. Reduction of submissions on changes/variations
2. Inspection of quality systems

Quality Risk Management

Pharmaceutical Development (Quality by Design)

Pharmaceutical Development (Q8)

Quality Systems

Quality Systems (Q10)

© Pharmaceutical Consultancy Services, All rights reserved.
International Harmonisation on Legislative Quality Vision:

Develop a *harmonized* pharmaceutical quality system applicable across the *life cycle* of the product emphasizing an integrated approach to quality *risk management* and *science* (ICH Brussels 2003)

ISO

Top management shall provide evidence of its commitment to the development and implementation of the quality management system and continually improve its effectiveness (ISO9000-2008)
Clauses are references to the ISO-chapters
Q10; PQS
<table>
<thead>
<tr>
<th>Standard QMS (Quality Management System) Elements</th>
</tr>
</thead>
<tbody>
<tr>
<td>Change Control/Management</td>
</tr>
<tr>
<td>Deviation/NC</td>
</tr>
<tr>
<td>CAPA</td>
</tr>
<tr>
<td>Complaints/Incidents</td>
</tr>
<tr>
<td>PQR/APR</td>
</tr>
<tr>
<td>Recall</td>
</tr>
<tr>
<td>Destruction</td>
</tr>
<tr>
<td>Vendor Management</td>
</tr>
<tr>
<td>Quality Control</td>
</tr>
<tr>
<td>On-going Stability</td>
</tr>
<tr>
<td>Enquiries</td>
</tr>
<tr>
<td>Validation/Verification/Qualification</td>
</tr>
<tr>
<td>External Inspections</td>
</tr>
<tr>
<td>Facilities / Utilities / Equipment</td>
</tr>
</tbody>
</table>
Q10; QUALITY MANAGEMENT

Q10: Pharmaceutical Quality System (PQS)

- ISO
- GMP
- ICH-Q8 and ICH-Q9

*Concept of Q10 is broader than GMP*

Q10 objectives

- Achieve product realization
- Establish and maintain a state of control
- Facilitate continual improvement

*Life-cycle approach*
Based on (enablers)

- Knowledge
  *Subject Matter Experts – SME introduced by ASTM2500-

- Risk Management
  *Based on ICH-Q9*

*A more science based approach as underlying theme.*

MANAGEMENT IS HELD RESPONSIBLE
Q10; QUALITY MANAGEMENT

Controls (1)
- Process Performance
- Product Quality Monitoring

Controls (2)
- Change Management
- CAPA
  - Correction (direct related to specific batch/event)
  - Corrective Action (broader concept to avoid re-occurrence)
  - Preventative Action (concept of avoiding –future- risks)

Controls (3)
- MANAGEMENT REVIEW
Management Review

- Senior Management should be responsible for:
  - *Pharmaceutical Quality System Governance*
  - PQS, to be suitable and effective
  - Assessing the Conclusions on periodic review;
    1. process/product
    2. Pharmaceutical Quality System (PQS)

Compared with GMP Part 1 - Old Chapter 2 section 3

*Key Personnel includes the head of Production, the head of Quality Control, and if at least one of these persons is not responsible for the release of products the authorised person(s) designated for the purpose. Normally key posts should be occupied by full-time personnel. The heads of Production and Quality Control must be independent from each other*
1.5 Senior management has the ultimate responsibility to ensure an effective Pharmaceutical Quality System is in place, adequately resourced and that roles, responsibilities, and authorities are defined, communicated and implemented throughout the organisation. Senior management’s leadership and active participation in the Pharmaceutical Quality System is essential. This leadership should ensure the support and commitment of staff at all levels and sites within the organisation to the Pharmaceutical Quality System.

1.6 There should be periodic management review, with the involvement of senior management, of the operation of the Pharmaceutical Quality System to identify opportunities for continual improvement of products, processes and the system itself.
Management Responsibilities

- Process Performance & Product Quality Monitoring System
- Corrective Action & Preventive Action (CAPA) System
- Change Management System
- Management Review

Enablers

- Knowledge Management
- Quality Risk Management
Risk (ICH-Q9 definition)

- Probability of occurrence of harm
- Severity of that harm

Prime importance: protection of the patient

Note: included within term “patient” is: the to be vaccinated recipient.

Systematics:

- Formal / Informal
- Multi-disciplinary
- Examples in Q9: at least works as agenda(s)
Q9; QUALITY RISK MANAGEMENT

Integrated throughout Quality Management System:
- Documentation
- Training and education
- Quality defects
- Auditing / Inspection
- Periodic review
- Change management / change control
- Continual improvement
- ........

Inspectorates / PIC/S:
- Develop training programme on QRM for inspectors
- Develop guidance for assessment of QRM implementation in industry
- Update PIC/S Site Master File format with QRM
Concept includes (not limited)

- Risk:
  - Identification
  - Analysis
  - Evaluation
  - Control
- FMEA – studies (as an example)
- Impact Assessments
  - Change Management
  - Deviations / NCMR
  - CAPA
- DATA gathering
**Notes:**

- Risk to quality is just one component of the overall risk!
- Product quality should be maintained throughout the product life cycle
- Risk management in pharma industry means protection of the patients by managing the risk to quality
(PIC/S) PHARMACEUTICAL INSPECTION CONVENTION
PIC (Pharmaceutical Inspection Convention) was founded in October 1970 by EFTA (European Free Trade Association) under the title of “The Convention for the Mutual Recognition of Inspections in Respect of the Manufacture of Pharmaceutical Products”.

Started with 10 members (European), followed by others (8), including Australia, until 1993.

PIC Scheme (Cooperation) was formed on 2 November 1995. PIC and the PIC Scheme, which operate together in parallel, are jointly referred to as **PIC/S. USA is a member since 2011**
PIC/S

- PIC/S' mission is "to lead the international development, implementation and maintenance of harmonised Good Manufacturing Practice (GMP) standards and quality systems of inspectorates in the field of medicinal products"
- 46 Countries
- EMA, WHO and UNICEF are Partnering with PIC/s
The need to form the PIC Scheme became necessary when it was realised that an incompatibility between PIC and European law did not permit individual EU countries that were members of PIC to sign agreements with other countries seeking to join PIC.

PIC/S provides an active and constructive co-operation in the field of GMP (Good Manufacturing Practice). The purpose of PIC/S is to facilitate the networking between participating authorities and the maintenance of mutual confidence, the exchange of information and experience in the field of GMP and related areas, and the mutual training of GMP inspectors.

Interesting publications:
- PI 032-2
- PI 012-3
- PI 007-6
- PI 014-3

Where to find them!
http://www.picscheme.org/publication.php
The need to form the PIC/S Scheme became necessary when it was realised that an incompatibility between PIC and European law did not permit individual EU countries that were members of PIC to sign agreements with other countries seeking to join PIC.

PIC/S provides an active and constructive co-operation in the field of GMP (Good Manufacturing Practice). The purpose of PIC/S is to facilitate the networking between participating authorities and the maintenance of mutual confidence, the exchange of information and experience in the field of GMP and related areas, and the mutual training of GMP inspectors.
OVERVIEW PDA TR`S 2013/2014/2015

2013:
• TR 60 – 64
• TR 54 – 3, TR 54 – 2
• Review TR 43, TR 33, TR 3

2014:
• TR 65 – 68
• TR 54 – 4
• Review TR 13

2015:
• Points to consider for Aseptic Processing Task Force; Part 1: January
OVERVIEW PDA TR`S 2013/2014/2015

2013:

• TR 60 – Process Validation: A lifecycle approach
• TR 61 – Steam in place
• TR 62 – Recommended practices for manual aseptic processes
• TR 63 – Quality requirements for the extemporaneous preparation of clinical trial materials
• TR 64 – Active temperature-controlled systems
• TR 54 – 2 (Annex 1), TR 54 – 3 (Annex 2)
• Review TR 43, TR 33, TR 3
OVERVIEW PDA TR`S 2013/2014/2015

2014/15:

- **TR 65** — Technology Transfer
- **TR 66** — Application of Single-Use Systems in pharmaceutical manufacturing
- **TR 67** — Exclusion of objectionable microorganisms from nonsterile pharmaceuticals, medical devices and cosmetics
- **TR 68** — Risk-Based approach for prevention and management of drug shortage
- **TR 69** - Bioburden and Biofilm Management in Pharmaceutical Drug Substance Manufacturing (very recent)
- **TR 54** — 4 (Annex 3)
- **Review TR 13** - Fundamentals of an Environmental Monitoring Program
THANK YOU FOR YOUR ATTENTION